GlassScriptPhysician profile
David Earl Yardley
NPI 1548253560
$6,692.07
in general payments reported to CMS, 2019-2025
24 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,786 · 2020: $215 · 2021: $696 · 2022: $457 · 2023: $1,250 · 2024: $158 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759 · Travel and Lodging: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.24 |
| Travel and Lodging | $778.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,408.41 | 2019-2025 | |
| Abbott Laboratories | $1,353.16 | 2019-2025 | Jot Dx, Cardiomems, Merlin@Home |
| Terumo Medical Corporation | $1,224.57 | 2019 | |
| Philips North America LLC | $995.48 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.51 | 2019-2023 | Lifevest |
| Endologix LLC | $187.30 | 2024-2025 | Torus Stent Graft System, Endocross Device |
| Shockwave Medical, INC | $159.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $139.71 | 2019-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $136.07 | 2025 | Optimizer |
| Novo Nordisk INC | $115.43 | 2025 | Wegovy |
| Tactile Systems Technology INC | $111.57 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Heartflow, INC. | $103.18 | 2025 | |
| Pfizer INC. | $98.72 | 2019-2021 | |
| Medtronic, INC. | $88.78 | 2022-2023 | Corevalve Evolut R |
| Amarin Pharma, INC. | $76.39 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $57.88 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $54.67 | 2020-2025 | Eliquis |
| Acist Medical Systems, INC. | $41.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.00 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $28.33 | 2021 | |
| Silk Road Medical, INC. | $27.70 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Amgen INC. | $21.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.03 | 2019 | |
| Medline Industries LP | $14.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yardley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.